On June 26, 2024, Verona Pharmaceuticals announced that its new medication, Ensifentrine (Ohtuvayre), was approved by the U.S. Food and Drug Administration (FDA) for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). We encourage all patients diagnosed with COPD to be tested for Alpha-1 Antitrypsin Deficiency. Learn about our free, confidential testing.
Click here to read more about Ensifentrine.
